223126-68-9

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 223126-69-0 3-(4-hydroxyphenyl)-2-methyl-2-phenoxypropionic acid ethyl ester 
• 401468-50-6 3-(4-benzyloxyphenyl)-3-hydroxy-2-phenoxy-2-methylpropionic acid ethyl ester 
• 42412-84-0 ethyl 2-phenoxypropionate 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 836-42-0 4-benzyloxybenzyl chloride 

Downstream Products

• 853260-14-7 3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ethyl ester 
• 698347-45-4 3-{4-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]phenyl}-2-methyl-2-phenoxypropionic acid ethyl ester 
• 401468-49-3 3-{4-[2-(2-Biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]-phenyl}-2-methyl-2-phenoxypropionic acid 
• 401791-04-6 2-Methyl-3-(4-{2-[5-methyl-2-cyclohexyl-oxazol-4-yl]-ethoxy}-phenyl)-2-phenoxypropionic Acid Ethyl Ester 
• 401790-93-0 (R)-3-{4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl}-2-phenoxypropionic acid ethyl ester 
• 401790-95-2 (S)-3-{4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl}-2-phenoxypropionic acid ethyl ester 
• 401790-98-5 (R)-2-methyl-3{4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)-ethoxy]phenyl}-2-phenoxypropionic acid ethyl ester 
• 401790-99-6 (S)-2-methyl-3{4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)-ethoxy]phenyl}-2-phenoxypropionic acid ethyl ester 
• 401790-94-1 3-{4-[2-(2-Phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic Acid Ethyl Ester 
• 401790-97-4 2-methyl-3-{4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)-ethoxy]-phenyl}-2-phenoxy-propionic acid ethyl ester 
• 401789-88-6 (S)-3-{4-[2-(2-Phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy propionic acid 
• 401468-52-8 (S)-(-)-3-(4-hydroxyphenyl)-2-methyl-2-phenoxypropionic acid ethyl ester 
• 401468-51-7 (R)-(+)-3-(4-hydroxyphenyl)-2-methyl-2-phenoxypropionic acid ethyl ester 
• 223126-69-0 3-(4-hydroxyphenyl)-2-methyl-2-phenoxypropionic acid ethyl ester 

Relevant academic research and scientific papers

PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compou

PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compou

Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes

PPARγ and 11β-HSD1 are attractive therapeutic targets for type 2 diabetes. However, PPARγ agonists induce adipogenesis, which causes the side effect of weight gain, whereas 11β-HSD1 inhibitors prevent adipogenesis and may be beneficial for the treatment of obesity in diabetic patients. For the first time, we designed, synthesized a series of α-aryloxy-α-methylhydrocinnamic acids as dual functional agents which activate PPARγ and inhibit 11β-HSD1 simultaneously. The compound 11e exhibited the most potent inhibitory activity compared to that of the lead compound 2, with PPARγ (EC50 = 6.76 μM) and 11β-HSD1 (IC50 = 0.76 μM) in vitro. Molecular modeling study for compound 11e was also presented. Compound 11e showed excellent efficacy for lowering glucose, triglycerides, body fat, in well established mice and rats models of diabetes and obesity and had a favorable ADME profile.

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/ γ Agonists

The design and synthesis of the dual peroxisome proliferator activated receptor (PPAR) α/γ agonist (S)-2-methyl-3-{4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)ethoxy]phenyl} -2-phenoxypropionic acid (2) for the treatment of type 2 diabetes and associated d

Amidocarboxylic acid derivatives

Amidocarboxylic acid derivatives of the formula: wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; X represents a substituted or unsubstituted aryl group, etc.,; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.; and pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as the active ingredient of pharmaceutical compositions. They may be used to treat specified diseases, including diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.